Fractalkine – a local inflammatory marker aggravating platelet activation at the vulnerable plaque

Summary

Chemokines play an important role in inducing chemotaxis of cells, piloting white blood cells in immune surveillance and are crucial parts in the development and progression of atherosclerosis. Platelets are mandatory players in the initiation of atherosclerotic lesion formation and are susceptible targets for and producers of chemokines. Several chemokine receptors on platelets have been described previously, amongst them CX₃CR1, the receptor for fractalkine. The unique chemokine fractalkine (CX₃CL1, FKN) exists as a soluble as well as a membrane-anchored glycoprotein. Its essential role in the formation of atherosclerotic lesions and atherosclerosis progression has been impressively described in mouse models. Moreover, fractalkine induces platelet activation and adhesion via a functional fractalkine receptor (CX₃CR1) expressed on the platelet surface. Platelet activation via the FKN/CX₃CR1-axis triggers leukocyte adhesion to activated endothelium, and fractalkine-induced platelet P-selectin is mandatory for leukocyte recruitment under arterial flow conditions. This review summarises the role of fractalkine as a potential local inflammatory mediator which influences platelet activation in the setting of atherosclerosis. Beyond that, aspects of a potential interaction between fractalkine and platelet responsiveness to antiplatelet drugs are described. Furthermore, the possible impact of high-density lipoprotein cholesterol (HDL-C) on atherosclerosis progression, platelet activation and fractalkine signalling are discussed.

Keywords

Fractalkine - platelet activation - atherosclerosis - HDL

• References

• 1 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 2 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
• 3 Nahrendorf M, Aikawa E, Figueiredo JL. et al. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: Implications for fxiii therapy and antithrombin use in myocardial infarction. Eur Heart J 2008; 29: 445-454.
• 4 Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14: 55-61.
• 5 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
• 6 Yla-Herttuala S, Bentzon JF, Daemen M. et al. Stabilisation of atherosclerotic plaques. Position paper of the european society of cardiology (esc) working group on atherosclerosis and vascular biology. Thromb Haemost 2011; 106: 1-19.
• 7 Massberg S, Brand K, Gruner S. et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
• 8 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein e. Nat Med 2003; 09: 61-67.
• 9 Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
• 10 Weber C. Platelets and chemokines in atherosclerosis: Partners in crime. Circ Res 2005; 96: 612-616.
• 11 Massberg S, Konrad I, Schurzinger K. et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 2006; 203: 1221-1233.
• 12 Struyf S, Burdick MD, Proost P. et al. Platelets release cxcl4l1, a nonallelic variant of the chemokine platelet factor-4/cxcl4 and potent inhibitor of angiogenesis. Circ Res 2004; 95: 855-857.
• 13 Brandt E, Petersen F, Ludwig A. et al. The beta-thromboglobulins and platelet factor 4: Blood platelet-derived cxc chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol 2000; 67: 471-478.
• 14 Theilmeier G, Michiels C, Spaepen E. et al. Endothelial von willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 2002; 99: 4486-4493.
• 15 Schwarz UR, Kobsar AL, Koksch M. et al. Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and cd40 ligand/p-selectin expression by cyclic nucleotide-regulated pathways in human platelets. Biochem Pharmacol 2000; 60: 1399-1407.
• 16 Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010; 30: 2341-2349.
• 17 Andre P, Prasad KS, Denis CV. et al. Cd40l stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med 2002; 08: 247-252.
• 18 Henn V, Slupsky JR, Grafe M. et al. Cd40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
• 19 Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: Role of p-selectin and the p-selectin ligand, psgl-1. Thromb Haemost 1995; 74: 224-227.
• 20 Li N, Hu H, Lindqvist M. et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702-2708.
• 21 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
• 22 Gawaz M, Page S, Massberg S. et al. Transient platelet interaction induces mcp-1 production by endothelial cells via i kappa b kinase complex activation. Thromb Haemost 2002; 88: 307-314.
• 23 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-621.
• 24 Hohensinner PJ, Niessner A, Huber K. et al. Inflammation and cardiac outcome. Curr Opin Infect Dis 2011; 24: 259-264.
• 25 Yu X, Dluz S, Graves DT. et al. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992; 89: 6953-6957.
• 26 Sheikine YA, Hansson GK. Chemokines as potential therapeutic targets in atherosclerosis. Curr Drug Targets 2006; 07: 13-27.
• 27 Eriksson EE. Mechanisms of leukocyte recruitment to atherosclerotic lesions: Future prospects. Curr Opin Lipidol 2004; 15: 553-558.
• 28 Veillard NR, Kwak B, Pelli G. et al. Antagonism of rantes receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94: 253-261.
• 29 Montecucco F, Braunersreuther V, Lenglet S. et al. Cc chemokine ccl5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J. 2011 epub ahead of print.
• 30 Gawaz M, Brand K, Dickfeld T. et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis 2000; 148: 75-85.
• 31 Gawaz M, Neumann FJ, Dickfeld T. et al. Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation 1998; 98: 1164-1171.
• 32 Bazan JF, Bacon KB, Hardiman G. et al. A new class of membrane-bound chemokine with a cx3c motif. Nature 1997; 385: 640-644.
• 33 Kowalska MA, Ratajczak MZ, Majka M. et al. Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets. Blood 2000; 96: 50-57.
• 34 Abi-Younes S, Sauty A, Mach F. et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 2000; 86: 131-138.
• 35 Boehlen F, Clemetson KJ. Platelet chemokines and their receptors: What is their relevance to platelet storage and transfusion practice?. Transfus Med 2001; 11: 403-417.
• 36 Clemetson KJ, Clemetson JM, Proudfoot AE. et al. Functional expression of ccr1, ccr3, ccr4, and cxcr4 chemokine receptors on human platelets. Blood 2000; 96: 4046-4054.
• 37 Onuffer JJ, Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: Recent developments. Trends Pharmacol Sci 2002; 23: 459-467.
• 38 Gear AR, Suttitanamongkol S, Viisoreanu D. et al. Adenosine diphosphate strongly potentiates the ability of the chemokines mdc, tarc, and sdf-1 to stimulate platelet function. Blood 2001; 97: 937-945.
• 39 Suttitanamongkol S, Gear AR. Adp receptor antagonists inhibit platelet aggregation induced by the chemokines sdf-1, mdc and tarc. FEBS Lett 2001; 490: 84-87.
• 40 Koenen RR, von Hundelshausen P, Nesmelova IV. et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 2009; 15: 97-103.
• 41 Harrison JK, Jiang Y, Chen S. et al. Role for neuronally derived fractalkine in mediating interactions between neurons and cx3cr1-expressing microglia. Proc Natl Acad Sci USA 1998; 95: 10896-10901.
• 42 Harrison JK, Jiang Y, Wees EA. et al. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol 1999; 66: 937-944.
• 43 Combadiere C, Potteaux S, Gao JL. et al. Decreased atherosclerotic lesion formation in cx3cr1/apolipoprotein e double knockout mice. Circulation 2003; 107: 1009-1016.
• 44 Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in cx3cr1−/− mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111: 333-340.
• 45 Teupser D, Pavlides S, Tan M. et al. Major reduction of atherosclerosis in fractalkine (cx3cl1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci USA 2004; 101: 17795-17800.
• 46 Landsman L, Bar-On L, Zernecke A. et al. Cx3cr1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009; 113: 963-972.
• 47 McDermott DH, Halcox JP, Schenke WH. et al. Association between polymorphism in the chemokine receptor cx3cr1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89: 401-407.
• 48 McDermott DH, Fong AM, Yang Q. et al. Chemokine receptor mutant cx3cr1-m280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003; 111: 1241-1250.
• 49 Moatti D, Faure S, Fumeron F. et al. Polymorphism in the fractalkine receptor cx3cr1 as a genetic risk factor for coronary artery disease. Blood 2001; 97: 1925-1928.
• 50 Wong BW, Wong D, McManus BM. Characterization of fractalkine (cx3cl1) and cx3cr1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002; 11: 332-338.
• 51 Kim KW, Vallon-Eberhard A, Zigmond E. et al. In vivo structure/function and expression analysis of the cx3c chemokine fractalkine. Blood 2011; 118: e156-167.
• 52 Tarozzo G, Campanella M, Ghiani M. et al. Expression of fractalkine and its receptor, cx3cr1, in response to ischaemia-reperfusion brain injury in the rat. Eur J Neurosci 2002; 15: 1663-1668.
• 53 Umehara H, Bloom E, Okazaki T. et al. Fractalkine and vascular injury. Trends Immunol 2001; 22: 602-607.
• 54 Greaves DR, Hakkinen T, Lucas AD. et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001; 21: 923-929.
• 55 Damas JK, Boullier A, Waehre T. et al. Expression of fractalkine (cx3cl1) and its receptor, cx3cr1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005; 25: 2567-2572.
• 56 Ikejima H, Imanishi T, Tsujioka H. et al. Upregulation of fractalkine and its receptor, cx3cr1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J 2010; 74: 337-345.
• 57 Soriano SG, Amaravadi LS, Wang YF. et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 2002; 125: 59-65.
• 58 Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145: 341-355.
• 59 Imai T, Hieshima K, Haskell C. et al. Identification and molecular characterization of fractalkine receptor cx3cr1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-530.
• 60 Tacke F, Alvarez D, Kaplan TJ. et al. Monocyte subsets differentially employ ccr2, ccr5, and cx3cr1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194.
• 61 Schulz C, Schafer A, Stolla M. et al. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: A critical role for p-selectin expressed on activated platelets. Circulation 2007; 116: 764-773.
• 62 Schafer A, Schulz C, Fraccarollo D. et al. The cx3c chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol 2007; 27: 55-62.
• 63 Goda S, Imai T, Yoshie O. et al. Cx3c-chemokine, fractalkine-enhanced adhesion of thp-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 2000; 164: 4313-4320.
• 64 Fong AM, Robinson LA, Steeber DA. et al. Fractalkine and cx3cr1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998; 188: 1413-1419.
• 65 Meyer dos Santos S, Klinkhardt U, Scholich K. et al. The cx3c chemokine fractalkine mediates platelet adhesion via the von willebrand receptor glycoprotein ib. Blood 2011; 117: 4999-5008.
• 66 Schafer A, Schulz C, Eigenthaler M. et al. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 2004; 103: 407-412.
• 67 Zwaginga JJ, Torres HI, Lammers J. et al. Minimal platelet deposition and activation in models of injured vessel wall ensure optimal neutrophil adhesion under flow conditions. Arterioscler Thromb Vasc Biol 1999; 19: 1549-1554.
• 68 Postea O, Vasina EM, Cauwenberghs S. et al. Contribution of platelet cx3cr1 to platelet-monocyte complex formation and vascular recruitment during hyperlipidemia. Arterioscler Thromb Vasc Biol 2012; 32: 1186-1193.
• 69 Husberg C, Nygard S, Finsen AV. et al. Cytokine expression profiling of the myocardium reveals a role for cx3cl1 (fractalkine) in heart failure. J Mol Cell Cardiol 2008; 45: 261-269.
• 70 Xuan W, Liao Y, Chen B. et al. Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res 2011; 92: 385-393.
• 71 Koziolek MJ, Muller GA, Zapf A. et al. Role of cx3c-chemokine cx3c-l/fractalkine expression in a model of slowly progressive renal failure. Nephrol Dial Transplant 2010; 25: 684-698.
• 72 Yao K, Lu H, Huang R. et al. Changes of dendritic cells and fractalkine in type 2 diabetic patients with unstable angina pectoris: A preliminary report. Cardiovasc Diabetol 2011; 10: 50.
• 73 Shah R, Hinkle CC, Ferguson JF. et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 2011; 60: 1512-1518.
• 74 Geisler T, Grass D, Bigalke B. et al. The residual platelet aggregation after deployment of intracoronary stent (predict) score. J Thromb Haemost 2008; 06: 54-61.
• 75 Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-242.
• 76 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
• 77 Schafer A, Weinberger S, Flierl U. et al. Adp-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a p2y12-specific assay. Thromb Haemost 2008; 100: 618-625.
• 78 Gurbel PA, Bliden KP, Samara W. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the crest study. J Am Coll Cardiol 2005; 46: 1827-1832.
• 79 Glowczynska R, Malek LA, Spiewak M. et al. Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombo-sis--a case report and review of the literature. Int J Cardiol 2006; 111: 326-328.
• 80 Jin J, Kunapuli SP. Coactivation of two different g protein-coupled receptors is essential for adp-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-8074.
• 81 Flierl U, Fraccarollo D, Lausenmeyer E. et al. Fractakine activates a signal trans-duction pathway similar to P2Y12 and is associated with impaired clopidogrel responsiveness. Arterioscler Thromb Vasc Biol. 2012 epub ahead of print.
• 82 Brewer Jr HB. Clinical review: The evolving role of hdl in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 2011; 96: 1246-1257.
• 83 Gordon T, Castelli WP, Hjortland MC. et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977; 62: 707-714.
• 84 Assmann G, Gotto Jr AM. Hdl cholesterol and protective factors in atherosclerosis. Circulation 2004; 109: III8-14.
• 85 Sattler KJ, Herrmann J, Yun S. et al. High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention. Eur Heart J 2009; 30: 1894-1902.
• 86 Ghazzal ZB, Dhawan SS, Sheikh A. et al. Usefulness of serum high-density lipo-protein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. Am J Cardiol 2009; 103: 902-906.
• 87 Tardif JC, Gregoire J, L'Allier PL. et al. Effects of reconstituted high-density lipo-protein infusions on coronary atherosclerosis: A randomized controlled trial. J Am Med Assoc 2007; 297: 1675-1682.
• 88 Bursill CA, Castro ML, Beattie DT. et al. High-density lipoproteins suppress che-mokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 2010; 30: 1773-1778.
• 89 Di Bartolo BA, Nicholls SJ, Bao S. et al. The apolipoprotein a-i mimetic peptide etc-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis 2011; 217: 395-400.
• 90 Yvan-Charvet L, Kling J, Pagler T. et al. Cholesterol efflux potential and anti-inflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010; 30: 1430-1438.
• 91 Nicholls SJ, Brewer HB, Kastelein JJ. et al. Effects of the cetp inhibitor evacetrapib administered as monotherapy or in combination with statins on hdl and ldl cholesterol: A randomized controlled trial. J Am Med Assoc 2011; 306: 2099-2109.
• 92 Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-572.
• 93 Barlage S, Boettcher D, Boettcher A. et al. High density lipoprotein modulates platelet function. Cytometry A 2006; 69: 196-199.
• 94 Brown DA. Lipid rafts, detergent-resistant membranes, and raft targeting signals. Physiology (Bethesda) 2006; 21: 430-439.
• 95 Fallahi-Sichani M, Linderman JJ. Lipid raft-mediated regulation of g-protein coupled receptor signaling by ligands which influence receptor dimerization: A computational study. PLoS One 2009; 04: e6604.
• 96 Quinton TM, Kim S, Jin J. et al. Lipid rafts are required in galpha(i) signaling downstream of the p2y12 receptor during adp-mediated platelet activation. J Thromb Haemost 2005; 03: 1036-1041.
• 97 Calkin AC, Drew BG, Ono A. et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009; 120: 2095-2104.